A new market study, titled “Global Markets for Infectious Disease Treatments”, has been featured on WiseGuyReports.
The global market for Infectious Diseases (treatment, vaccines and diagnostics), in 2016, was valued at $59.7 billion, expected to grow to about $99 billion by 2022, at a CAGR of 8.9%.
Key growth markets include the Western Pacific and South-East Asia regions, though all regions have a high single digit growth when look at the overall infectious diseases landscape. America is the biggest market, followed by Europe, throughout the forecast period. Higher cost of treatment accounts for the larger market values in these two markets, even though the number of cases might be lower than other parts of the world.
Therapeutics for hepatitis C and HIV/AIDS are high-value markets, with hepatitis C markets growing at a CAGR of 13% and HIV/AIDS at a CAGR of 5.1%. Malaria, primarily in the African markets, and tuberculosis in South-East Asian countries, are other diseases with high growth poised for the next few years. Rise of resistant forms of the disease, drive towards drugs with newer mechanism of action (MoA) to combat resistance, and initiatives to increase diagnostic and treatment access by WHO and national authorities will drive the market.
In 2016, the global market for HIV therapeutics was valued at $21.9 billion, set to increase to nearly $29.5 billion by 2022, at a CAGR of 5.1%. America was the largest market (more than 88% market share) primarily due to high prices of first-line treatment options and high coverage of treatment. Based on prevalence, Africa houses about 70% of the individuals living with HIV globally, but only comprises about 7% of the total global market share. This is driven by interventions to reduce prices and WHO measures to ensure increase treatment coverage.
Among vaccines, influenza vaccines have the highest market value market with growth in the next couple of years being driven by conversion to quadrivalent vaccines and immunization of the elderly population. In terms of growth, vaccines for Zika and Dengue have high growth potential. Markets for vaccines for conditions such as viral hemorrhagic fevers depend on the severity and occurrence of the next outbreak and the decision of health authorities to incorporate immunization against the disease in its national programs.
From the perspective of demand, the market for dengue vaccines was $63.8 million in 2016, expected to grow to $930 million at a CAGR of 32%, from 2017 to 2022. Industry experts expect the supply and time to approvals and incorporation in national regulatory programs to slow down market growth. The Central and South America, South-East Asia and Western Pacific regions will be the growth drivers for this market.
For diagnostics, HIV/AIDS, tuberculosis and malaria are some of the high-value markets, due to high disease burden as well as the need of clinically confirmed diagnosis. Detection kits for RSV, herpes and influenza are under-utilized in developing economies as the clinician can diagnose these, based on clinical findings to a certain accuracy. Thus, unless the cost of diagnostic kits is lowered, diagnosis of disease will be a combination of a clinician’s observation of the symptoms and recommendation of a diagnostic test. Resistance to current standard of therapy is a major issue and newer detection kits also feature assays to identify that.Report Scope:
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.
The market is categorized based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships in a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries, which are described in detail in the subsequent section.
– 84 data tables and 23 additional tables
– An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
– Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
– Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
– Examination of technological developments, future trends, and emerging opportunities
– Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by region
– Patent analyses
– Company profiles of major players in the market, including Alere (now Abbott), Novartis, Roche Diagnostics, Sanofi Pasteur and Siemens Healthineers
ALERE (NOW ABBOTT)
JANSSEN, PHARMACEUTICAL COMPANY OF JOHNSON & JOHNSON
MEDICINES FOR MALARIA VENTURE (MMV)
ORASURE TECHNOLOGIES INC.
SANOFI, SANOFI PASTEUR
SEQIRUS, A CSL COMPANY
View Detailed Report at https://www.wiseguyreports.com/reports/3037917-global-markets-for-infectious-disease-treatments
Table of Contents
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview
Chapter 4 Disease Overview
Chapter 5 Markets and Forecast
Chapter 6 Market Dynamics
Chapter 7 Antibiotic Resistance
Chapter 8 Research and Development
Chapter 9 Next Generation Predictive Tools
Chapter 10 Patent Analysis
Chapter 11 Company Profiles
Chapter 12 Appendix
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)